Viemed Healthcare, Inc. (VMD) P/E Ratio History
Fairly ValuedTrading at 30.8x, near 5Y avg of 30.8x · 75th percentile · In line with own history · Data 2018–2026
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, Viemed Healthcare, Inc. (VMD) trades at a price-to-earnings ratio of 30.8x, with a stock price of $11.39 and trailing twelve-month earnings per share of $0.37.
The current P/E is roughly in line with its 5-year average of 30.8x. Over the past five years, VMD's P/E has ranged from a low of 20.3x to a high of 66.0x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, VMD trades at a 34% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, VMD commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VMD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VMD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
VMD P/E vs Peers
Respiratory and sleep therapy devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 75.9 | - | +103% | |
| $2B | 30.2 | - | +53% | |
| $2B | 18.8 | 0.93Best | +23% | |
| $1B | 9.2Lowest | - | +179% | |
| $26B | 25.7 | - | +224%Best | |
| $29B | 20.9 | 1.20 | +37% | |
| $17B | 30.5 | - | -25% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
VMD Historical P/E Data (2018–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $9.21 | $0.37 | 25.1x | -4% |
| FY2025 Q4 | Dec 31 2025 | $7.43 | $0.37 | 20.3x | -23% |
| FY2025 Q3 | - | $6.79 | $0.33 | 20.8x | -21% |
| FY2025 Q2 | Jun 30 2025 | $6.91 | $0.33 | 20.8x | -21% |
| FY2025 Q1 | Mar 31 2025 | $7.28 | $0.29 | 25.0x | -5% |
| FY2024 Q4 | - | $8.02 | $0.27 | 29.6x | +13% |
| FY2024 Q3 | Sep 30 2024 | $7.33 | $0.26 | 28.2x | +8% |
| FY2024 Q2 | Jun 30 2024 | $6.55 | $0.24 | 27.8x | +6% |
| FY2024 Q1 | Mar 31 2024 | $9.43 | $0.26 | 36.6x | +40% |
| FY2023 Q4 | Dec 31 2023 | $7.85 | $0.26 | 30.7x | +17% |
| FY2023 Q3 | Sep 30 2023 | $6.73 | $0.23 | 29.4x | +12% |
| FY2023 Q2 | Jun 30 2023 | $9.78 | $0.18 | 53.0x | +102% |
| FY2023 Q1 | Mar 31 2023 | $9.66 | $0.15 | 66.0x | +152% |
| FY2022 Q4 | Dec 31 2022 | $7.56 | $0.15 | 49.7x | +90% |
| FY2022 Q3 | Sep 30 2022 | $6.00 | $0.19 | 31.5x | +20% |
| FY2022 Q2 | - | $5.38 | $0.20 | 26.4x | +1% |
| FY2022 Q1 | - | $4.98 | $0.22 | 22.3x | -15% |
| FY2021 Q4 | Dec 31 2021 | $5.22 | $0.22 | 23.7x | -9% |
| FY2021 Q3 | - | $5.55 | $0.24 | 23.1x | -12% |
| FY2021 Q2 | Jun 30 2021 | $7.15 | $0.27 | 26.5x | +1% |
| FY2021 Q1 | Mar 31 2021 | $10.12 | $0.71 | 14.3x | -46% |
| FY2020 Q4 | - | $7.76 | $0.78 | 9.9x | -62% |
| FY2020 Q3 | Sep 30 2020 | $8.64 | $0.72 | 12.0x | -54% |
| FY2020 Q2 | - | $9.60 | $0.72 | 13.3x | -49% |
| FY2020 Q1 | - | $4.76 | $0.27 | 17.6x | -33% |
| FY2019 Q4 | - | $6.20 | $0.21 | 29.5x | +13% |
| FY2019 Q3 | Sep 30 2019 | $6.92 | $0.23 | 30.5x | +16% |
| FY2019 Q2 | Jun 30 2019 | $6.84 | $0.22 | 31.5x | +20% |
| FY2019 Q1 | Mar 31 2019 | $4.90 | $0.25 | 19.9x | -24% |
| FY2018 Q4 | Dec 31 2018 | $3.80 | $0.26 | 14.8x | -44% |
| FY2018 Q3 | Sep 30 2018 | $5.18 | $0.18 | 28.9x | +10% |
| FY2018 Q2 | Jun 30 2018 | $3.51 | $0.23 | 15.3x | -42% |
| FY2018 Q1 | Mar 31 2018 | $2.50 | $0.23 | 10.7x | -59% |
Average P/E for displayed period: 26.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VMD — Frequently Asked Questions
Quick answers to the most common questions about buying VMD stock.
What is VMD's P/E ratio?
Viemed Healthcare, Inc. (VMD) trailing twelve-month P/E ratio is 30.8x, based on TTM diluted EPS of $0.37. The 5-year average P/E is 30.8x and the historical range spans 20.3x to 66.0x.
Is VMD stock overvalued or undervalued?
VMD trades at 30.8x P/E, near its 5-year average of 30.8x. The 75th percentile ranking within the 20.3x–66.0x historical range places valuation within normal bounds.
Is VMD stock expensive?
VMD is fairly valued relative to its own history. The current P/E of 30.8x is near the 5-year average of 30.8x (75th percentile of historical range).
What is VMD's historical P/E range?
Over the past 5 years, VMD's P/E ratio has ranged from 20.3x to 66.0x, with a median of 27.8x and an average of 30.8x. The current P/E of 30.8x places the stock at the 75th percentile of this range. Full historical data spans 2018–2026.
How does VMD's P/E compare to the S&P 500?
VMD trades at 30.8x P/E versus the S&P 500 median of 25.1x. The 23% premium to the market typically reflects higher expected earnings growth or quality.
How does VMD's valuation compare to Healthcare peers?
Viemed Healthcare, Inc. P/E of 30.8x compares to the Healthcare sector median of 22.9x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is VMD's PEG ratio?
VMD PEG ratio is N/A, based on a P/E of 30.8x and EPS growth of 32.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is VMD's earnings yield?
VMD earnings yield is 3.25%, the inverse of its 30.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.